Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CASSAVA SCIENCES, INC.

(SAVA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Cassava Sciences : to Present at H.C. Wainwright's 23rd Annual Global Investment Conference

09/09/2021 | 08:15am EDT

AUSTIN, Texas, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that management will present at H.C. Wainwright’s 23rd Annual Global Investment Conference, a virtual event that takes place September 13-15, 2021.

Cassava Sciences’ presentation is a ‘fireside chat’ with Vernon T. Bernardino, PhD., Managing Director, Biotechnology Equity Research, at H.C. Wainwright.

Event details follow: 
Date:Monday, September 13th
Time:7:00 a.m. Eastern Time
Webcast:https://www.CassavaSciences.com/company-presentations

Cassava Sciences’ fireside chat will be available for replay for 90 days following the conference on www.CassavaSciences.com in the ‘Investors’ section.

About Alzheimer’s Disease
Alzheimer’s disease is a progressive brain disorder that destroys memory and thinking skills. As of 2020, there were approximately 50 million people worldwide living with dementia, a figure expected to increase to over 150 million by 2050.1 The annual global cost of dementia is now above $1 trillion, according to Alzheimer’s Disease International, a charitable organization.

About Cassava Sciences, Inc.
Cassava Sciences’ mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer’s disease.

Simufilam and SavaDx were both developed in-house. Cassava Sciences owns worldwide development and commercial rights to its research programs in Alzheimer’s disease, and related technologies, without royalty obligations to any third party.

For more information, please visit https://www.CassavaSciences.com

Contact Information:
Eric Schoen, Chief Financial Officer
Cassava Sciences, Inc.
eschoen@CassavaSciences.com
(512) 501-2450

1Alzheimer's Disease International, Dementia Statistics, available on-line and accessed September 8, 2021.

 


Primary Logo

Source: Cassava Sciences, Inc.

2021 GlobeNewswire, Inc., source Press Releases

All news about CASSAVA SCIENCES, INC.
10:31aThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Act..
BU
10/25SHAREHOLDER ALERT : Pomerantz Law Firm Reminds Shareholders with Losses on their Investmen..
PR
10/25CASSAVA SCIENCES 24 HOUR DEADLINE AL : Former Louisiana Attorney General and Kahn Swick & ..
PR
10/25CASSAVA SCIENCES DEADLINE ALERT : Bragar Eagel & Squire, P.C. Reminds Investors that a Cla..
BU
10/25SAVA FINAL DEADLINE TOMORROW : ROSEN, NATIONAL TRIAL COUNSEL, Encourages Cassava Sciences,..
PR
10/25LAST DAY TO ACTIVELY PARTICIPATE IN : Bronstein, Gewirtz & Grossman, LLC
BU
10/23SAVA INVESTOR REMINDER : Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securiti..
BU
10/22CASSAVA SCIENCES 96 HOUR DEADLINE AL : Former Louisiana Attorney General and Kahn Swick & ..
BU
10/22DEADLINE IN 4 DAYS : Kessler Topaz Meltzer & Check, LLP Reminds Investors of Class Action ..
BU
10/22CASSAVA SCIENCES : SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securiti..
PR
More news
Analyst Recommendations on CASSAVA SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -19,0 M - -
Net Debt 2021 - - -
P/E ratio 2021 -79,1x
Yield 2021 -
Capitalization 1 887 M 1 887 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 18,9x
Nbr of Employees 11
Free-Float 93,6%
Chart CASSAVA SCIENCES, INC.
Duration : Period :
Cassava Sciences, Inc. Technical Analysis Chart | SAVA | US14817C1071 | MarketScreener
Technical analysis trends CASSAVA SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 47,17 $
Average target price 140,67 $
Spread / Average Target 198%
EPS Revisions
Managers and Directors
Remi Barbier Chairman, President & Chief Executive Officer
Eric J. Schoen Chief Financial Officer
Nadav Friedmann Director, Chief Operating & Medical Officer
James W. Kupiec Chief Clinical Development Officer
Michael Zamloot Senior Vice President-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
CASSAVA SCIENCES, INC.591.64%1 913
GILEAD SCIENCES, INC.16.25%84 845
BIONTECH SE258.67%71 229
WUXI APPTEC CO., LTD.23.63%64 399
REGENERON PHARMACEUTICALS22.57%59 906
VERTEX PHARMACEUTICALS-22.12%47 992